XML 30 R24.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statement Details (Tables)

3 Months Ended

Mar. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):


		March 31, 2025				December 31, 2024
Prepaid research and development expenses		$	7,359			$	1,947
Interest and other non-trade receivables			1,714				1,609
Other prepaid expenses			2,208				2,510
Total other current assets		$	11,281			$	6,066

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


		March 31, 2025				December 31, 2024
Accrued compensation		$	5,026			$	2,832
Accrued research and development expenses			11,819				14,453
Accrued contract termination costs			2,825				2,767
Other accrued expenses			11,584				9,920
Total accrued expenses		$	31,254			$	29,972

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2025 (in thousands):


		Three Months Ended March 31, 2025
		2012 Purchase and Sale Agreement				2020 Purchase and Sale Agreement				Total
Liabilities related to the sales of future royalties, net – beginning balance		$	7,197			$	84,579			$	91,776
Non-cash royalty revenue			(1,756	)			(8,704	)			(10,460	)
Non-cash interest expense			672				4,302				4,974
Amortization of transaction costs			—				32				32
Liabilities related to the sales of future royalties, net – ending balance		$	6,113			$	80,209			$	86,322